Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,263 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Copd Clear all
Completed Phase 2 Interventional

BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease (COPD)

NCT01551953
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tai chi, Mind-body breathing, Education
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 28, 2026, 11:03 PM EDT
Not listed Not applicable Interventional

Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis

NCT04677465
View directory record Official record
Conditions
Chronic Bronchitis
Interventions
RheOx Bronchial Rheoplasty, Sham Procedure
Device
Lead sponsor
Gala Therapeutics, Inc.
Industry
Eligibility
35 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 28, 2026, 11:03 PM EDT
Completed Not applicable Interventional

Anxiety and COPD Evaluation

NCT02740465
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Anxiety Inventory for Respiratory Disease (AIR), Hospital Anxiety and Depression Scale (HADS)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 28, 2026, 11:03 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT00665600
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Levalbuterol HCl, Albuterol Sulfate, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years to 99 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
20
States / cities
Carmichael, California • Spring Valley, California • Wheat Ridge, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 28, 2026, 11:03 PM EDT
Recruiting Not applicable Interventional

Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)

NCT04179981
View directory record Official record
Conditions
Sleep Apnea Syndrome, Obstructive Sleep Apnea, COPD, Overlap Syndrome, Quality of Life, Neurocognitive Function, Sleepiness, Elderly, Positive Airway Pressure
Interventions
Positive airway pressure, Conservative care (control arm)
Device · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 28, 2026, 11:03 PM EDT
Completed Phase 3 Interventional

A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate 20 Mcg/0.5 mL in the Treatment of Patients With COPD

NCT00280371
View directory record Official record
Conditions
COPD
Interventions
Formoterol Fumarate
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
52
States / cities
Jasper, Alabama • Phoenix, Arizona • Buena Park, California + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2010 · Synced Oct 28, 2026, 11:03 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD

NCT02109406
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
AZD2115 Dose 1, AZD 2115, Dose 2, Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
3
States / cities
Clearwater, Florida • Charleston, South Carolina • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 28, 2026, 11:03 PM EDT
Completed Phase 2 Interventional

A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.

NCT03636347
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency, Emphysema, COPD
Interventions
Placebo Oral Tablet, Alvelestat oral tablet - dose 1, Alvelestat oral tablet - dose 2
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 28, 2026, 11:03 PM EDT
Completed Phase 3 Interventional Results available

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01957163
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF, VI, UMEC, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Jasper, Alabama • Clearwater, Florida • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 28, 2026, 11:03 PM EDT
Withdrawn Not applicable Interventional

Crossover Blinded Trial of Cell Therapy Versus Placebo in COPD

NCT03228121
View directory record Official record
Conditions
COPD, Emphysema or COPD, Chronic Bronchitis
Interventions
Treatment Then Placebo, Placebo Then Treatment
Procedure
Lead sponsor
Lung Institute
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 28, 2026, 11:03 PM EDT
Completed Phase 4 Interventional Results available

Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation

NCT00181207
View directory record Official record
Conditions
COPD, Chronic Bronchitis, Emphysema
Interventions
pneumatic vest, placebo pneumatic vest
Device · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 28, 2026, 11:03 PM EDT
Completed No phase listed Observational

Replication of the IMPACT COPD Trial in Healthcare Claims Data

NCT05062304
View directory record Official record
Conditions
COPD
Interventions
Fluticasone Furoate-Vilanterol Trifenatate, Furoate-umeclidinium-vilanterol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 120 Years
Enrollment
17,281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 28, 2026, 11:03 PM EDT
Completed Not applicable Interventional

Sustained Effects of Hypertonic Saline on Mucociliary Clearance in Subjects With Chronic Bronchitis

NCT01792271
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD, Chronic Bronchitis
Interventions
Inhaled 7% HS (NaCl) home treatment
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 28, 2026, 11:03 PM EDT
Completed No phase listed Observational

Long-term Observational Study of the Safety of Roflumilast

NCT03381573
View directory record Official record
Conditions
COPD
Interventions
Roflumilast
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
135,856 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 28, 2026, 11:03 PM EDT
Not yet recruiting Not applicable Interventional

WearME-Pro Phase II: Remote Use Usability and Longitudinal Validation Study (Patch Form Factor).

NCT07430605
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
WearME-Pro Patch System, FDA-cleared handheld spirometer (reference comparator), Cardea SOLO ECG patch (optional subset; exploratory HR reference)
Device
Lead sponsor
LASARRUS Clinic and Research Center
Industry
Eligibility
21 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Baltimore, Maryland • Salisbury, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 28, 2026, 11:03 PM EDT
Completed Not applicable Interventional

A Six Month Randomized Controlled Clinical Trial of Lung Flute in Patients With Chronic Obstructive Pulmonary Disease

NCT01186822
View directory record Official record
Conditions
COPD
Interventions
Lung Flute
Device
Lead sponsor
Nicolaas J Smit PhD
Industry
Eligibility
30 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2015 · Synced Oct 28, 2026, 11:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Developing a COPD Case Finding Methodology for Primary Care

NCT01880177
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
40 Years and older
Enrollment
346 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
4
States / cities
Lexington, Kentucky • Ann Arbor, Michigan • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Oct 28, 2026, 11:03 PM EDT
Completed Phase 4 Interventional Results available

Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations

NCT05292053
View directory record Official record
Conditions
Copd
Interventions
TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 28, 2026, 11:03 PM EDT
Completed Not applicable Interventional

Effectiveness of Home Automated Telemanagement in Chronic Obstructive Pulmonary Disorder

NCT00752531
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Home Automated Telemanagement (HAT)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 28, 2026, 11:03 PM EDT
Completed Phase 3 Interventional

A Pilot Study of Montelukast Sodium (Singulair) in Older Adults With Asthma or Chronic Obstructive Pulmonary Disease

NCT00162864
View directory record Official record
Conditions
Asthma, COPD
Interventions
montelukast sodium
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 24, 2006 · Synced Oct 28, 2026, 11:03 PM EDT
Completed Not applicable Interventional

Feasibility of a Multi Component Intervention in Patients With Severe Dyspnea and Obesity

NCT03836547
View directory record Official record
Conditions
COPD, Emphysema, Lung Diseases
Interventions
Coaching and Weight Loss for patients with dyspnea, Active Control
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 28, 2026, 11:03 PM EDT
Completed Not applicable Interventional

A Phase I Study of iPS Cell Generation From Patients With COPD

NCT01860898
View directory record Official record
Conditions
Thoracic Diseases, Respiratory Tract Diseases, Cancer of Lung, Cancer of the Lung, Lung Cancer, Lung Diseases, Obstructive, COPD, Pulmonary Emphysema, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell
Interventions
Skin Biopsy
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 28, 2026, 11:03 PM EDT
Completed Phase 4 Interventional Results available

Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPD

NCT01745848
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Roflumilast
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 28, 2026, 11:03 PM EDT
Completed Phase 2 Interventional

Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and Inflammation in COPD

NCT00648245
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
BIO-11006 Inhalation Solution, Placebo, BIO-11006
Drug
Lead sponsor
BioMarck Pharmaceuticals, Ltd.
Industry
Eligibility
45 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Glendale, Arizona • Los Angeles, California • Bay Pines, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2011 · Synced Oct 28, 2026, 11:03 PM EDT